{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T16:02:21Z","timestamp":1770825741730,"version":"3.50.1"},"reference-count":31,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCO"],"published-print":{"date-parts":[[1999,5]]},"abstract":"<jats:p>PURPOSE: To correlate cytogenetic abnormalities with clinical presentation and outcome in Burkitt-like, small noncleaved non-Burkitt's lymphoma (SNC-NB).<\/jats:p><jats:p>PATIENTS AND METHODS: Thirty-nine patients with SNC-NB lymphoma and a clonal karyotype were evaluated between January 1989 and January 1996. All were from British Columbia, Canada, underwent uniform clinical staging, and were treated on investigational protocols by a small group of clinicians.<\/jats:p><jats:p>RESULTS: Three groups of patients were identified by clonal karyotype on cytogenetic analysis: (1) those with a c-myc translocation (n = 11); (2) those with dual translocation of c-myc and bcl-2 (n = 13); and (3) those with other cytogenetic abnormalities (n = 15). The c-myc group was younger, presented with earlier stage de novo disease, and had a better clinical prognostic factor profile. The dual-translocation and other groups were older and presented in advanced stage with poorer prognostic features, and a larger proportion of the dual-translocation group patients had transformed from previously diagnosed follicular lymphoma. The median overall survival (OS) time for all patients was 5 months. The median OS time for the dual-translocation group was only 2.5 months, as compared with 7 months and 8 months for the c-myc and other group, respectively (P &lt; .001). There were no survivors beyond 7 months among the dual-translocation group, as opposed to 32% and 25% 2-year OS rates in the c-myc and other group.<\/jats:p><jats:p>CONCLUSION: SNC-NB lymphoma is a clinically and cytogenetically heterogenous disease. Dual translocation of c-myc and bcl-2 is characterized by a rapid clinical course and extremely poor outcome. This latter entity may represent the most clinically aggressive lymphoma thus far characterized and warrants intensive investigational treatment where feasible.<\/jats:p>","DOI":"10.1200\/jco.1999.17.5.1558","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T10:08:12Z","timestamp":1487930892000},"page":"1558-1558","source":"Crossref","is-referenced-by-count":146,"title":["Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation"],"prefix":"10.1200","volume":"17","author":[{"given":"Nicol","family":"Macpherson","sequence":"first","affiliation":[{"name":"From the Divisions of Medical Oncology, Hematology, and Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver and Victoria, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lesack","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Hematology, and Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver and Victoria, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Klasa","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Hematology, and Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver and Victoria, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doug","family":"Horsman","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Hematology, and Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver and Victoria, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph M.","family":"Connors","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Hematology, and Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver and Victoria, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Barnett","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Hematology, and Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver and Victoria, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"From the Divisions of Medical Oncology, Hematology, and Pathology, British Columbia Cancer Agency and University of British Columbia, Vancouver and Victoria, British Columbia, Canada."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"233","reference":[{"key":"R1-1558","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.11.3909"},{"key":"R2-1558","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830460408"},{"key":"R3-1558","doi-asserted-by":"crossref","unstructured":"Zech L, Haglund U, Nilsson K, et al: Characteristic chromosomal abnormalities in biopsies and lymphoid-cell lines from patients with Burkitt and non-Burkitt lymphomas. Int J Cancer 17:47,1987-56,","DOI":"10.1002\/ijc.2910170108"},{"key":"R4-1558","unstructured":"Klein G: Comparative action of and 2 in B-cell malignancy. Cancer Cells 3:141,1991-143,mycbcl-"},{"key":"R5-1558","doi-asserted-by":"publisher","DOI":"10.1038\/320760a0"},{"key":"R6-1558","doi-asserted-by":"crossref","unstructured":"Griep AE, Westphal H: Anti-sense Myc sequences induce differentiation of F9 cells. Proc Natl Acad Sci U S A 85:6805,1988-6810,","DOI":"10.1073\/pnas.85.18.6806"},{"key":"R7-1558","unstructured":"Fukuhara S, Rowley JD, Variakojis D: Chromosomal abnormalities in poorly differentiated lymphocytic lymphoma. Cancer Res 39:3119,1979-3128,"},{"key":"R8-1558","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.10.5.1901"},{"key":"R9-1558","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.386.bloodjournal882386"},{"key":"R10-1558","unstructured":"Brito-Babapulle V, Crawford A, Khokhar T, et al: Translocations t(14;18) and t(8;14) with rearranged 2 and c- in a case presenting as B-ALL (L3). Leukemia 5:83,1991-87,bcl-myc"},{"key":"R11-1558","unstructured":"Gauwerky CE, Hoxie J, Nowell PC, et al: Pre-B-cell leukemia with a t(8;14) translocation is preceded by follicular lymphoma. Oncogene 2:431,1988-435,"},{"key":"R12-1558","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198805263182106"},{"key":"R13-1558","doi-asserted-by":"publisher","DOI":"10.1159\/000205054"},{"key":"R14-1558","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V62.5.1142.bloodjournal6251142"},{"key":"R15-1558","doi-asserted-by":"crossref","unstructured":"Pegoraro L, Palumbo A, Erikson J, et al: A 14;18 and 8;14 translocation in a cell line derived from an acute B-cell leukemia. Proc Natl Acad Sci U S A 81:971,1984-972,","DOI":"10.1073\/pnas.81.22.7166"},{"key":"R16-1558","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.2870020211"},{"key":"R17-1558","doi-asserted-by":"publisher","DOI":"10.3109\/10428199309148200"},{"key":"R20-1558","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1958.10501452"},{"key":"R21-1558","doi-asserted-by":"crossref","unstructured":"Cox DR: Regression models and life-tables. J R Stat Soc B 34:187,1972-202,","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"R22-1558","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199309303291402"},{"key":"R23-1558","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(75)91142-3"},{"key":"R25-1558","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.5.1282.1282"},{"key":"R26-1558","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.2763089.x"},{"key":"R27-1558","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.8.2124.2124"},{"key":"R28-1558","doi-asserted-by":"crossref","unstructured":"Nunez G, London L, Hockenberry D, et al: Deregulated 2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 144:3602,1990-3610,bcl-","DOI":"10.4049\/jimmunol.144.9.3602"},{"key":"R29-1558","doi-asserted-by":"publisher","DOI":"10.1038\/348334a0"},{"key":"R30-1558","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(86)90361-2"},{"key":"R31-1558","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(92)90123-T"},{"key":"R32-1558","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(89)90174-8"},{"key":"R33-1558","doi-asserted-by":"publisher","DOI":"10.1038\/349254a0"},{"key":"R34-1558","doi-asserted-by":"publisher","DOI":"10.1006\/excr.1995.1083"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.1999.17.5.1558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T10:40:26Z","timestamp":1692700826000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.1999.17.5.1558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,5]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1999,5]]}},"alternative-id":["10.1200\/JCO.1999.17.5.1558"],"URL":"https:\/\/doi.org\/10.1200\/jco.1999.17.5.1558","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[1999,5]]}}}